A clinical case of the effectiveness of the anti PD-1 inhibitor (prolgolimab) in the treatment of metastatic melanoma

• DOI: 10.21518/ms2024-515
• Publication Date: 2024-12-25T19:16:49Z
• Authors: P. V. Golubev; T. I. Deshkina; L. V. Bolotina; E. S. Kuzmina; S. A. Golubeva; I. A. Pokataev; V. N. Galkin
• Keywords: 03 medical and health sciences; 0302 clinical medicine

Melanoma of the skin is one most aggressive cancers. Until recently, metastatic melanoma was associated with an extremely negative prognosis: median overall survival for this category patients no more than 7–8 months. Thanks to improvement therapeutic approaches, it possible achieve a significant increase in life expectancy unresectable and process. Currently, several targeted immunotherapy options are available treatment or melanoma. These approaches have thoroughly taken leading place everyday clinical practice made change natural history disease: today about 30–60% can survive 5 years more. There 3 immune response checkpoint inhibitors related PD-1 receptor blockers registered our country: pembrolizumab, nivolumab Russian-made prolgolimab. In article, we describe case effective patient generalized using domestic drug The article also provides brief description main studies on molecules their indirect comparison foreign analogues.